Modulating Platelet Reactivity with GLP-1RAs in Diabetes: Mechanistic Insights, Potential Benefits, and Clinical Limitations in Atherothrombotic Prevention

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have redefined cardiovascular medicine, reducing major adverse cardiovascular events (MACE) through pleiotropic mechanisms that transcend glycemic and weight control. While their cardioprotective benefits are well-established, their direct impact on platelet activity—a key driver of atherothrombotic risk—remains a compelling frontier. This narrative review first addresses the heightened atherothrombotic risk characteristic of patients with diabetes and the clinical challenges posed by their suboptimal response to standard antiplatelet regimens. Subsequently, it explores experimental evidence on the antiplatelet properties of GLP-1RAs. Mechanistically, GLP-1RAs exert a dual inhibitory action: direct modulation involves the activation of platelet-surface GLP-1 receptors, triggering the PKA signaling cascade and VASP phosphorylation, which in turn suppresses calcium mobilization and aggregation. Indirectly, these agents restore vascular health by enhancing nitric oxide bioavailability, preserving endothelial glycocalyx integrity, and shifting perivascular adipose tissue toward an anti-inflammatory phenotype. Furthermore, GLP-1RAs mitigate the pro-thrombotic milieu by attenuating glycemic variability and systemic inflammatory cascades. However, these compelling experimental findings do not currently translate into clear clinical impact, and a clinical gap persists: while reductions in mortality and stroke risk are firmly established, the specific efficacy of GLP-1RAs in preventing acute coronary events is still evolving. In conclusion, GLP-1RAs emerge as multifaceted tools with significant cardiovascular protection, offering a synergistic approach to secondary prevention in high-risk cardiometabolic patients; however, how these favorable outcomes are mediated by antiplatelet properties warrants dedicated prospective investigations to translate experimental findings into clinical certainty.

Authors

Institutions

Publication Details

Journal
Journal of Cardiovascular Pharmacology
Published
2026-11-19
DOI
https://doi.org/10.1097/fjc.0000000000001903
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Modulating Platelet Reactivity with GLP-1RAs in Diabetes: Mechanistic Insights, Potential Benefits, and Clinical Limitations in Atherothrombotic Prevention

Francesco Prati, Valeria Cammalleri, Fabio Mangiacapra, Gian Paolo Ussia et al.
Journal of Cardiovascular Pharmacology
Antiplatelet Therapy and Cardiovascular Diseases
article

Modulating Platelet Reactivity with GLP-1RAs in Diabetes: Mechanistic Insights, Potential Benefits, and Clinical Limitations in Atherothrombotic Prevention

Francesco Prati, Valeria Cammalleri, Fabio Mangiacapra, Gian Paolo Ussia, Elisabetta Ricottini, Annunziata Nusca, Laura Gatto, Maria Pia Di Bitonto, Antonio Emanuele Lentini, Stefano Beato, Arianna Rasi, Christian Santella
article en

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have redefined cardiovascular medicine, reducing major adverse cardiovascular events (MACE) through pleiotropic mechanisms that transcend glycemic and weight control. While their cardioprotective benefits are well-established, their direct impact on platelet activity—a key driver of atherothrombotic risk—remains a compelling frontier. This narrative review first addresses the heightened atherothrombotic risk characteristic of patients with diabetes and the clinical challenges posed by their suboptimal response to standard antiplatelet regimens. Subsequently, it explores experimental evidence on the antiplatelet properties of GLP-1RAs. Mechanistically, GLP-1RAs exert a dual inhibitory action: direct modulation involves the activation of platelet-surface GLP-1 receptors, triggering the PKA signaling cascade and VASP phosphorylation, which in turn suppresses calcium mobilization and aggregation. Indirectly, these agents restore vascular health by enhancing nitric oxide bioavailability, preserving endothelial glycocalyx integrity, and shifting perivascular adipose tissue toward an anti-inflammatory phenotype. Furthermore, GLP-1RAs mitigate the pro-thrombotic milieu by attenuating glycemic variability and systemic inflammatory cascades. However, these compelling experimental findings do not currently translate into clear clinical impact, and a clinical gap persists: while reductions in mortality and stroke risk are firmly established, the specific efficacy of GLP-1RAs in preventing acute coronary events is still evolving. In conclusion, GLP-1RAs emerge as multifaceted tools with significant cardiovascular protection, offering a synergistic approach to secondary prevention in high-risk cardiometabolic patients; however, how these favorable outcomes are mediated by antiplatelet properties warrants dedicated prospective investigations to translate experimental findings into clinical certainty.

Journal of Cardiovascular Pharmacology
Università Campus Bio-Medico (IT), Azienda Ospedaliera San Giovanni Addolorata (IT), Campus Bio Medico University Hospital (IT)
Antiplatelet Therapy and Cardiovascular Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon